| Literature DB >> 30650545 |
Marina Blenski1, Ralph H Kehlenbach2.
Abstract
<span class="Gene">LRRC59 (<span class="Gene">leucine-rich repeat-containing protein 59) is a tail-anchored protein with a single transmembrane domain close to its C-terminal end that localizes to the endoplasmic reticulum (ER) and the nuclear envelope. Here, we investigate the mechanisms of membrane integration of LRRC59 and its targeting to the inner nuclear membrane (INM). Using purified microsomes, we show that LRRC59 can be post-translationally inserted into ER-derived membranes. The TRC-pathway, a major route for post-translational membrane insertion, is not required for LRRC59. Like emerin, another tail-anchored protein, LRRC59 reaches the INM, as demonstrated by rapamycin-dependent dimerization assays. Using different approaches to inhibit importin α/β-dependent nuclear import of soluble proteins, we show that the classic nuclear transport machinery does not play a major role in INM-targeting of LRRC59. Instead, the size of the cytoplasmic domain of LRRC59 is an important feature, suggesting that targeting is governed by passive diffusion.Entities:
Keywords: LRRC59; TRC40; inner nuclear membrane; tail-anchored proteins
Mesh:
Substances:
Year: 2019 PMID: 30650545 PMCID: PMC6359192 DOI: 10.3390/ijms20020334
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Models for targeting of membrane proteins to the inner nuclear membrane. (A) Active-transport-model. After insertion into the endoplasmic reticulum (ER), proteins expose a nuclear localization signal (NLS) to the cytoplasm, which can be recognized by nuclear transport receptors. After translocation from the outer nuclear membrane (ONM) to the inner nuclear membrane (INM), the complex is dissociated by nuclear RanGTP. (B) Diffusion-and-retention model. Membrane proteins diffuse passively through the nuclear pore complex (NPC) and are sequestered at the INM upon interaction with the nuclear lamina and/or chromatin. See text for details. Modified after reference [29].
Figure 2Posttranslational membrane insertion of LRRC59. (A) Schematic representation of full length LRRC59. The leucine rich repeat region (LRR), the putative coiled-coil domain and the transmembrane domain (TMD) are indicated. (B) Opsin-tagged LRRC59 (HZZ-LRRC59-op) and emerin (HZZ-emerin-op) were produced in vitro by coupled transcription-translation reactions in the absence (−) or presence (+) of rough microsomes (RM) and with (+) or without (−) the addition of puromycin. Proteins were analyzed by SDS-PAGE, followed by immunoblotting using antibodies against the opsin-tag and calnexin as loading control. G indicates the glycosylated forms of LRRC59-opsin and emerin-opsin. (C) Quantification of the results in (B). The error bars indicate the standard deviation from the mean of six independent experiments. (D) Membrane insertion of HZZ-LRRC59-op or HZZ-emerin-op after in vitro transcription-translation reactions into EDTA/high-salt (EK-RM) or trypsin-treated (T-RM) microsomes with (+) or without (−) addition of puromycin. Proteins were analyzed by SDS-PAGE, followed by immunoblotting using antibodies against the opsin-tag and PDI as loading control.
Figure 3The TRC-pathway is not required for membrane insertion of LRRC59. (A) In vitro transcribed/translated HZZ-LRRC59-opsin or emerin-opsin was subjected to membrane integration assays using rough microsomes (RM) in the absence (−) or presence (+) of 5 or 10 µM GST-CAML-N, as indicated. Reactions were analyzed by SDS-PAGE followed by immunoblotting, using antibodies against the opsin-tag and against calnexin as loading control. Note that the emerin-construct used in this experiment lacks the N-terminal HZZ-tag. G indicates the glycosylated forms of LRRC59-opsin and emerin-opsin. (B) As (A), using MBP-WRBcc instead of GST-CAML-N. (C) The rabbit reticulocyte lysate used for coupled transcription-translation reactions was immunodepleted using antibodies against TRC40 (+) or IgG (−) as control. Depletion was analyzed by SDS-PAGE, followed by Western-blotting and Ponceau S- (bottom) and immunostaining using an antibody against TRC40. (D) Membrane insertion of HZZ-LRRC59-opsin and HZZ-emerin-opsin using TRC40- or mock-depleted lysates (C) for coupled in vitro transcription and translation with (+) or without (−) the addition of rough microsomes (RM), as indicated. Proteins were analyzed by SDS-PAGE, followed by immunoblotting using antibodies against PDI and the opsin-tag. (E) Quantification of membrane insertion reactions as in (D). Individual values were normalized to a reaction with mock-depleted lysate. Error bars indicate the standard deviation from the mean of five independent experiments.
Figure 4LRRC59 is targeted to the INM. (A) HeLa cells were grown on coverslips and analyzed by indirect immunofluorescence using antibodies against LRRC59 and lamin A/C. (B) HeLa cells were transfected with plasmids coding for HA-LRRC59, mCherry-LRRC59 or mCherry-FRB-LRRC59. Cells were fixed and analyzed directly (mCherry-LRRC59 and mCherry-FRB-LRRC59) or after immunostaining using an anti-HA antibody. (C) Schematic overview for the rapamycin-induced dimerization assay. Cells are transiently transfected with plasmids coding for the nuclear reporter EGFP2-GST-M9-FKBP12 (green) and the protein of interest tagged with mCherry and FRB (red). The addition of rapamycin (orange hexagon) leads to the dimerization of the FRB- and FKBP12-cassettes and to a recruitment of the reporter to the INM. (D) HeLa cells were co-transfected with plasmids coding for EGFP2-GST-M9-FKBP12 and mCherry-FRB-LRRC59, mCherry-FRB-emerin or WRB-FRB-HA, respectively, and treated with (+) or without (−) rapamycin for 10 min. Cells were fixed and analyzed directly (mCherry-FRB-LRRC59, mCherry-FRB-emerin) or after immunostaining using an anti-HA antibody (WRB-FRB-HA).
Figure 5Importin β is not required for INM-targeting of LRRC59. (A) U2OS cells were treated with control siRNAs or siRNAs against importin β. After 48 h, cells were subjected to indirect immunofluorescence using antibodies against LRRC59 or, on separate slides, importin β. (B) HeLa cells were transfected with control siRNAs or siRNAs against importin β and with plasmids coding for EGFP2-GST-M9-FKBP12, mCherry-FRB-LRRC59 and NES-mTagBFP2-cNLS. After 48 h, cells were treated with rapamycin at room temperature for 10 min, fixed, immunostained using antibodies against importin β and analyzed by confocal microscopy. (C) Quantification of rapamycin assays as in (B). The percentage of cells responding to rapamycin with a recruitment of EGFP2-GST-M9-FKBP12 to the nuclear periphery was plotted against the time after addition of the drug. Error bars indicate the standard deviation from the mean of five independent experiments, counting 100 (1–4 min) or 250 (10 min) cells per time point. (D) HeLa cells were co-transfected with plasmids coding for EGFP2-GST-M9-FKBP12, mCherry-FRB-LRRC59, NES-mTagBFP2-cNLS and FLAG-Bimax2 or pcDNA3 as a control, respectively. After 48 h, cells were treated with rapamycin for 10 min, fixed, immunostained using antibodies against the FLAG-tag and analyzed by confocal microscopy. (E) Quantification of rapamycin assays as in (D), plotting the percentage of cells responding to rapamycin with a recruitment of the reporter protein to the nuclear periphery. Error bars indicate the standard deviation from the mean of 3 independent experiments, counting 200 cells each.
Figure 6The size of the cytoplasmic domain of LRRC59 affects its targeting to the INM. (A) Schematic overview of LRRC59-constructs of different sizes. (B) HeLa cells were co-transfected with plasmids coding for EGFP2-GST-M9-FKBP12 and mCherry-FRB-LRRC59, mCherry-FRB-MBP-LRRC59 or HA-FRB-LRRC59, respectively. Plasmid concentrations were adjusted for similar expression levels of the different LRRC59 forms. After 48 h, cells were treated with or without rapamycin for 1–10 min, fixed and analyzed by fluorescence microscopy. Representative images for the 10 min-time point are shown. (C) Quantification of the experiment in (B). The percentage of cells responding to rapamycin with a recruitment of the reporter to the nuclear periphery was plotted against the time after addition of the drug. Error bars indicate the standard deviation from the mean of at least 4 independent experiments, counting 100 cells per time point. (D) HeLa cells were transfected with plasmids coding for EGFP2-MBP-M9-FKBP12 and mCherry-FRB-LRRC59, mCherry-FRB-MBP-LRRC59 and mCherry-FRB-GST-LRRC59, respectively. Plasmid concentrations were adjusted for similar expression levels of the different LRRC59 constructs. After 48 h, cells were treated as described in panel (B). (E) Quantification as in (C) of the experiment in (D). Error bars indicate the standard deviation from the mean of 5 independent experiments, counting 100 cells per time point.